SCHEMBL20909892

SCHEMBL20909892

Cc1ccnc(N2CCNC2=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 1/20 0.47
▸ CCR5 P51681 1/20 0.47
▸ CCR8 P51685 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ TSHR P16473 1/20 0.44
▸ GRIN2D O15399 1/20 0.43
▸ GRIN3B O60391 1/20 0.43
▸ GRIN1 Q05586 1/20 0.43
▸ GRIN2A Q12879 1/20 0.43
▸ GRIN2B Q13224 1/20 0.43
▸ GRIN2C Q14957 1/20 0.43
▸ GRIN3A Q8TCU5 1/20 0.43
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3782058 0.81 CCR1 (0.52) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL20890601 0.80 MAP3K5 (0.41) CYP3A4TSHRKMT2ASMN1; SMN2MAP3K5
SCHEMBL12594227 0.80 NOS3 (0.45) CYP3A4CYP2C9CYP2C19TSHRMEN1
SCHEMBL19454936 0.77 TDO2 (0.48) CYP3A4TSHRGRIN2DGRIN3BGRIN1
SCHEMBL21858471 0.76 ADRB1 (0.60) ALDH1A1EGLN2KDM4ENOS3NOS2
SCHEMBL1569134 0.76 PIK3CA (0.55) —
SCHEMBL10275026 0.75 CCR1 (0.50) CCR1CCR5CCR8CYP3A4CYP2C9
SCHEMBL17263330 0.75 PIK3CA (0.61) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL1568266 0.75 KDM4C (0.50) TSHRPOLBSMN1; SMN2KDM4ENPC1
SCHEMBL12859179 0.74 CYP3A4 (0.48) CCR1CCR5CCR8CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102803250-A 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 NOVARTIS AG 2012-11-28 — — CN claimed
WO-2019074979-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF GIRAFPHARMA, LLC (US) 2019-04-18 — — WO disclosed
CN-102803250-B 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 NOVARTIS AG 2014-04-16 — — CN disclosed
CN-102803250-A 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 NOVARTIS AG 2012-11-28 — — CN disclosed
Send feedback